Analyzing Stevanato Group (NYSE:STVN) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ)

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Valuation and Earnings

This table compares Health Sciences Acquisitions Co. 2 and Stevanato Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A
Stevanato Group	$1.17 billion	N/A	$157.62 million	€0.47 ($0.49)	49.60

Stevanato Group has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Health Sciences Acquisitions Co. 2 and Stevanato Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0	0	0	0	0.00
Stevanato Group	0	1	5	0	2.83

Profitability

This table compares Health Sciences Acquisitions Co. 2 and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Stevanato Group	10.47%	9.86%	5.79%

Institutional & Insider Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Comparatively, 0.7% of Stevanato Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Summary

Stevanato Group beats Health Sciences Acquisitions Co. 2 on 8 of the 10 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.